AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16702815 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) with DMA formulation, 6.2 to 10.60 mg/m/cycle for 7-21 days
Number of subjects: 62
Study 16702815 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) with CD formulation, 12.60 mg/m/cycle for 21 days
Number of subjects: 62
Study 16702815 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) with CD formulation, 9.44 to 12.60 mg/m/cycle for 14 days
Number of subjects: 62
Study 16702815 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC)
Number of subjects: 62
Study 12620439 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) patch
Number of subjects: 122
Study 12620439 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) gel
Number of subjects: 122
Study 11762805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, bid. days 4-13)
Number of subjects: 240
Study 11762805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ciprofloxacin plus roxithromycin)
Number of subjects: 240
Study 11762805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9048239 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (10 mg) with leuprolide acetate (1 mg)
Number of subjects: 41
Study 9048239 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (1 mg) alone
Number of subjects: 41
Study 8106151 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiradoline (1 to 4 micrograms/kg)
Number of subjects: 4
Study 3219974 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitumor B (Chinese herbs)
Number of subjects: 6758
Study 3219974 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide (4‐Ethoxycarbophenylretinamide)
Number of subjects: 6758
Study 3219974 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 6758
Study 3219974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6758
Study 31902472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 283
Study 31902472 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 283
Study 29605753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1 - midwifery intervention involving oral health education, screening and referrals to existing dental pathways
Number of subjects: 638
Study 29605753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 - midwifery intervention plus dental intervention involving assessment/treatment from cost free local dental services
Number of subjects: 638
Study 29605753 — intervention group
Group type: COMPARATOR
Intervention: Control group - received oral health information at recruitment
Number of subjects: 638
Study 28864871 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg
Number of subjects: 75
Study 28864871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 25239521 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (135 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Number of subjects: 120
Study 25239521 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (1,250 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Number of subjects: 120
Study 22246377 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (0.12 pmol/kg/min) infusion for 6 hours
Number of subjects: 20
Study 22246377 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 6 hours
Number of subjects: 20
Study 20436265 — intervention group
Group type: EXPERIMENTAL
Intervention: E₂/DSP
Number of subjects: 106
Study 20436265 — intervention group
Group type: EXPERIMENTAL
Intervention: E₂/NETA
Number of subjects: 106
Study 20436265 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 106
Study 16777467 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessory knee joint mobilization (9-min, non-noxious, AP mobilization of the tibio-femoral joint)
Number of subjects: 38
Study 16777467 — intervention group
Group type: COMPARATOR
Intervention: Manual contact (control)
Number of subjects: 38
Study 16777467 — intervention group
Group type: COMPARATOR
Intervention: No-contact (control)
Number of subjects: 38
Study 16777467 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessory knee joint mobilization
Number of subjects: 38
Study 16223397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular approach
Number of subjects: 60
Study 16223397 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach
Number of subjects: 60
Study 16223397 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 12141068 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (30, 60 or 150 mg day-1)
Number of subjects: 100
Study 12141068 — intervention group
Group type: EXPERIMENTAL
Intervention: Levormeloxifene (1.25, 5, 10 or 20 mg day-1)
Number of subjects: 100
Study 12141068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10211854 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Jump (SJ) protocol
Number of subjects: 108
Study 10211854 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ) data
Number of subjects: 108
Study 10211854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation using PRESS
Number of subjects: 108
Study 7843430 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU IM FSH with or without 75 IU SC hCG
Number of subjects: 32
Study 7843430 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 IU FSH with or without 50 IU SC hCG
Number of subjects: 32
Study 7843430 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 or 225 IU IM hMG
Number of subjects: 32
Study 7843430 — intervention group
Group type: EXPERIMENTAL
Intervention: SC mini-dose hCG
Number of subjects: 32
Study 2388642 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified inverted walking stick (VC stick)
Number of subjects: 8
Study 2388642 — intervention group
Group type: COMPARATOR
Intervention: Straight walking stick
Number of subjects: 8
Study 2388642 — intervention group
Group type: COMPARATOR
Intervention: Parallel lines spaced every 12 in.
Number of subjects: 8
Study 571216 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% salt‐poor human albumin (1.5 ml/kg)
Number of subjects: 15
Study 571216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (7 ml/kg)
Number of subjects: 15
Study 571216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl in water (normal saline) (7 ml/kg)
Number of subjects: 15
Study 30796020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+0 schedule pneumococcal conjugate vaccine (PCV13)
Number of subjects: 402
Study 27598855 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 600 mg every week
Number of subjects: 1584
Study 27598855 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 1200 mg every other week
Number of subjects: 1584
Study 27598855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study 26051574 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy (hypertonic dextrose injection)
Number of subjects: 65
Study 23659362 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DSTE in patients with AF
Number of subjects: 20
Study 23659362 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study 21034693 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram + pindolol (5 mg tid)
Number of subjects: 30
Study 21034693 — intervention group
Group type: COMPARATOR
Intervention: citalopram + placebo
Number of subjects: 30
Study 21034693 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (meta-analysis)
Number of subjects: 30
Study 19425356 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal goals (autonomous interest)
Number of subjects: 0
Study 19425356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical goals (social expectation)
Number of subjects: 0
Study 17545881 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (2-4 times per week for 6 months)
Number of subjects: 561
Study 17416939 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 0
Study 17416939 — intervention group
Group type: COMPARATOR
Intervention: Timolol/dorzolamide combination therapy
Number of subjects: 0
Study 14657813 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 16 to 32 mg/kg/d for 6 days
Number of subjects: 391
Study 14657813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 14657813 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 391
Study 10609908 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverin 2 mg/ml
Number of subjects: 80
Study 10609908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 1 mg/ml
Number of subjects: 80
Study 10609908 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 0.5 mg/ml
Number of subjects: 80
Study 10609908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside 0.5 mg/ml
Number of subjects: 80
Study 10609908 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.9% (placebo)
Number of subjects: 80
Study 7815628 — intervention group
Group type: EXPERIMENTAL
Intervention: Artery sparing techniques
Number of subjects: 88
Study 7815628 — intervention group
Group type: EXPERIMENTAL
Intervention: Palomo procedure
Number of subjects: 88
Study 7815628 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected varicoceles (comparison group)
Number of subjects: 88
Study 2014087 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cefoxitin prophylaxis (3 doses)
Number of subjects: 113
Study 2014087 — intervention group
Group type: COMPARATOR
Intervention: Long-term cefoxitin prophylaxis (12 doses)
Number of subjects: 113
Study 7049077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (200 mg daily for 5 days)
Number of subjects: 0
Study 7049077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (concentration range 5 X 10(‐6) M to 5 X 10(‐3) M)
Number of subjects: 0
Study 7049077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine with dapsone
Number of subjects: 0
Study 7049077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (after ingestion)
Number of subjects: 0
Study 31116261 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day adjunctive minocycline for MDD
Number of subjects: 71
Study 31116261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 30672619 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (8% maltodextrin, CHO) during exercise
Number of subjects: 9
Study 30672619 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion (0% carbohydrate, PLA) during exercise
Number of subjects: 9
Study 30672619 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion during exercise
Number of subjects: 9
Study 27887769 — intervention group
Group type: COMPARATOR
Intervention: DPPOS participants
Number of subjects: 0
Study 25952728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400µg
Number of subjects: 16
Study 25952728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50μg
Number of subjects: 16
Study 25952728 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18µg
Number of subjects: 16
Study 25952728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (10nM, 100nM, 1μM)
Number of subjects: 16
Study 25952728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium (1μM)
Number of subjects: 16
Study 25952728 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (1μM)
Number of subjects: 16
Study 23154591 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan add-on group
Number of subjects: 303
Study 23154591 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy without ARB (control group)
Number of subjects: 303
Study 21252014 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOBYPASS (AdGVVEGF121.10NH) gene therapy
Number of subjects: 17
Study 21252014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18302016 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC prevention framework implementation monitoring system
Number of subjects: 12
Study 18302016 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC program implementation monitoring system
Number of subjects: 12
Study 16442668 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal foods
Number of subjects: 0
Study 16442668 — intervention group
Group type: COMPARATOR
Intervention: Snack foods
Number of subjects: 0
Study 12769153 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNu Multi Plus
Number of subjects: 20
Study 12769153 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI‐FREE Express
Number of subjects: 20
Study 12769153 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Blink‐N‐Clean
Number of subjects: 20
Study 12769153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens Plus
Number of subjects: 20
Study 12769153 — intervention group
Group type: COMPARATOR
Intervention: Control (no drops during recovery)
Number of subjects: 20
Study 11125686 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 3.0%
Number of subjects: 30
Study 11125686 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg
Number of subjects: 30
Study 11125686 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 30
Study 9235523 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 95
Study 9235523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 95
Study 9235523 — intervention group
Group type: EXPERIMENTAL
Intervention: Component C3 of complement
Number of subjects: 95
Study 9235523 — intervention group
Group type: COMPARATOR
Intervention: Transient ischaemic attack
Number of subjects: 95
Study 1610165 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal offered 60 min after exercise
Number of subjects: 13
Study 1610165 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal offered at random intervals (0, 30, 60, or 120 min after exercise)
Number of subjects: 13
Study 1610165 — intervention group
Group type: COMPARATOR
Intervention: Meal offered 60 min after a session without exercise
Number of subjects: 13
Study 3933035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate (25 mg)
Number of subjects: 7
Study 3933035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (25 mg)
Number of subjects: 7
Study 3933035 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 7
Study 29928114 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371 under fed condition
Number of subjects: 18
Study 29928114 — intervention group
Group type: COMPARATOR
Intervention: LCB01-0371 under fasting condition
Number of subjects: 18
Study 29928114 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371 under fed and fasting conditions
Number of subjects: 18
Study 29928114 — intervention group
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Number of subjects: 18
Study 26426458 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation (15 L/min of 100% oxygen via high-flow nasal cannula during laryngoscopy)
Number of subjects: 150
Study 26426458 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no supplemental oxygen during laryngoscopy)
Number of subjects: 150
Study 26426458 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation
Number of subjects: 150
Study 26426458 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 26426458 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation and usual care
Number of subjects: 150
Study 24630848 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal TDCS at 2 mA
Number of subjects: 53
Study 24630848 — intervention group
Group type: COMPARATOR
Intervention: Cathodal TDCS at 2 mA
Number of subjects: 53
Study 24630848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of stimulation (anodal and cathodal)
Number of subjects: 53
Study 24630848 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency difference of MEPs (anterior‐posterior stimulation minus latero‐medial stimulation)
Number of subjects: 53
Study 23681467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 50
Study 23681467 — intervention group
Group type: COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Number of subjects: 50
Study 19841160 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 10 to 20 mg/d
Number of subjects: 0
Study 19841160 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d
Number of subjects: 0
Study 18764914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung resection (lobectomy or pneumonectomy)
Number of subjects: 2
Study 17064591 — intervention group
Group type: EXPERIMENTAL
Intervention: SELDI‐TOF‐MS protein fingerprinting in serum
Number of subjects: 39
Study 17064591 — intervention group
Group type: EXPERIMENTAL
Intervention: m/z 3078.7 biomarker
Number of subjects: 39
Study 14646710 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (absorbed dose, 95 kGy)
Number of subjects: 61
Study 14646710 — intervention group
Group type: COMPARATOR
Intervention: Conventional gamma irradiated polyethylene (absorbed dose, 25-40 kGy)
Number of subjects: 61
Study 14646710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Highly cross-linked and Control)
Number of subjects: 61
Study 12074203 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 400 mg per day
Number of subjects: 98
Study 12074203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 10400278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise program
Number of subjects: 86
Study 10400278 — intervention group
Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 86
Study 7488449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator drug treatment for 12 weeks
Number of subjects: 18
Study 2035894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz TENS of the right hand for 45 minutes
Number of subjects: 8
Study 2035894 — intervention group
Group type: COMPARATOR
Intervention: Indifferent stimulation of the iliopsoas region (Control)
Number of subjects: 8
Study 7076372 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon group counseling
Number of subjects: 0
Study 7076372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29774787 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention bias to threat measured using eye gaze tracking
Number of subjects: 42
Study 29774787 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician rated severity of social anxiety
Number of subjects: 42
Study 28116649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept with radiation and concomitant temozolomide
Number of subjects: 59
Study 28116649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept with adjuvant temozolomide using the 5/28 regimen
Number of subjects: 59
Study 28116649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept with adjuvant temozolomide using the 21/28 day regimen
Number of subjects: 59
Study 28116649 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 59
Study 26730454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-60 mg/d or 80-120 mg/d)
Number of subjects: 825
Study 26730454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 24956970 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance training (12 weeks, 3 times per week at 50-70% of heart rate reserve)
Number of subjects: 120
Study 24956970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic dance training)
Number of subjects: 120
Study 21848526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of glutamate
Number of subjects: 9
Study 21848526 — intervention group
Group type: COMPARATOR
Intervention: Control condition (isotonic saline injection)
Number of subjects: 9
Study 19380868 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-7 (3 microg/kg and 30 microg/kg)
Number of subjects: 11
Study 19380868 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-7
Number of subjects: 11
Study 17474645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation in a subtropical climate (Spain)
Number of subjects: 96
Study 17474645 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation in a temperate climate (Norway)
Number of subjects: 96
Study 15710956 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (10-week smoking cessation program with behavior modification and nicotine gum)
Number of subjects: 5887
Study 15710956 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887
Study 15710956 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention
Number of subjects: 5887
Study 12089836 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computer animation
Number of subjects: 80
Study 12089836 — intervention group
Group type: COMPARATOR
Intervention: Written text (standard flyer)
Number of subjects: 80
Study 9879698 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM antibodies reacting with the terminal disaccharide of galactose (beta1‐3)N‐acetylgalactosamine
Number of subjects: 0
Study 8031424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 14
Study 8031424 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study 2700773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg dexamethasone suppression test (DST)
Number of subjects: 10
Study 2700773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg dexamethasone suppression test (DST) after lorazepam discontinuation
Number of subjects: 10
Study 2700773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg dexamethasone suppression test (DST) after theophylline administration
Number of subjects: 10
Study 166929 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/Hong Kong/68‐ts‐1 [E] (H3N2) virus
Number of subjects: 10